Lineage Announces Acquisition of NeuroAirmid Therapeutics
The acquisition includes a clinical-stage program for the treatment of Huntington's disease.
Story updates
09:03:17 PM UTC
SquawkNews
LINEAGE CELL THERAPEUTICS - ACQUISITION INCLUDES RIGHTS TO REGEN4HD PHASE 1B/2A TRIAL FOR HUNTINGTON
09:03:22 PM UTC
SquawkNews
Lineage acquired NeuroAirmid and worldwide rights to HUNT1, a clinical-stage Huntington’s disease therapy. It paid approximately $4.7M at closing; up to $5M is due after one year, with up to $48M in additional milestones.Material DetailsContext by AI AnalystThis acquisition adds a third clinical-st…
09:20:00 PM UTC
SquawkNews
Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics and secured an amended license from The Regents of the University of California, adding rights to the HUNT1 neural cell therapy program for Huntington's disease. The acquisition closed November 12, 2026, with upfront cash, shares and other…